LES ULIS, France--(BUSINESS WIRE)--On December 20th, a decree from the President of France was published in Le Journal Officiel* appointing Denis DELVAL CEO of LFB S.A. This decree follows the General Meeting of LFB SA and the meeting of its Board of Directors, which both took place on December 4th, 2017.
Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th, following Christian BÉCHON and Denis SOUBEYRAN’s departures.
A graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy, Denis DELVAL has a deep understanding of the pharmaceutical industry. He has held important marketing, sales and strategic positions in France, Europe and worldwide and has managed international partnerships within various pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was appointed General Manager of ALK France. In 2012, he also became Senior Vice President of the Danish pharmaceutical company specialized in allergy immunotherapy treatments. Denis DELVAL lectures at ESSEC business school and has also been Chairman of Lecrip.org, a healthcare think tank.
“I am proud to be appointed as CEO of LFB Group and to work for this company operating in a strategic sector. LFB produces therapeutics that are essential for the lives of thousands of patients, particularly in the rare disease field. I am fully aware of the challenges ahead and look forward to unleashing energies to make this pharmaceutical company successful in France and internationally.”
* The Official Journal of the French Republic.
About LFB Group
LFB is a biopharmaceutical group
that develops, manufactures, and markets medicinal products derived from
living matter for the treatment of serious and often rare diseases in
several major therapeutic fields, including Hemostasis, Immunology and
Intensive Care. LFB is the leading manufacturer of plasma-derived
medicinal products in France and 7th worldwide,
and is also among the leading European companies for the development of
new-generation medicinal products or treatments based on
biotechnologies. Through its constant research efforts, the LFB group
implements a growth strategy to expand its activities on international
markets. Today, LFB currently markets its products in almost 60
countries around the world with a global turnover of €518.9 million in
2016. LFB group employs more than 2300 people worldwide.
www.groupe-lfb.com
